PT  - JOURNAL ARTICLE
AU  - Neeltje van Doremalen
AU  - Trenton Bushmaker
AU  - Dylan H. Morris
AU  - Myndi G. Holbrook
AU  - Amandine Gamble
AU  - Brandi N. Williamson
AU  - Azaibi Tamin
AU  - Jennifer L. Harcourt
AU  - Natalie J. Thornburg
AU  - Susan I. Gerber
AU  - James O. Lloyd-Smith
AU  - Emmie de Wit
AU  - Vincent J. Munster
TI  - Aerosol and surface stability of HCoV-19 (SARS-CoV-2) compared to SARS-CoV-1
AID  - 10.1101/2020.03.09.20033217
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.03.09.20033217
4099  - http://medrxiv.org/content/early/2020/03/13/2020.03.09.20033217.short
4100  - http://medrxiv.org/content/early/2020/03/13/2020.03.09.20033217.full
AB  - A novel human coronavirus, now named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, referred to as HCoV-19 here) that emerged in Wuhan, China in late 2019 is now causing a pandemic1. Here, we analyze the aerosol and surface stability of HCoV-19 and compare it with SARS-CoV-1, the most closely related human coronavirus.2 We evaluated the stability of HCoV-19 and SARS-CoV-1 in aerosols and on different surfaces and estimated their decay rates using a Bayesian regression model (see Supplementary Appendix). All experimental measurements are reported as mean across 3 replicates.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). JOL-S and AG were supported by the Defense Advanced Research Projects Agency DARPA PREEMPT # D18AC00031, and JOL-S was supported by the U.S. National Science Foundation (DEB-1557022) and the Strategic Environmental Research and Development Program (SERDP, RCâ€26635) of the U.S. Department of Defense.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesdata is available upon request